Labyrinthine dysfunction

H8_LABYRDYSFUNC

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H83.2 Cause of death: ICD-10 — H83.2 2 out of 7 registries used, show all original rules.	28
4. Check minimum number of events None	28
5. Include endpoints None	28
6. Filter based on genotype QC (FinnGen only)	28

Control definitions (FinnGen only)

Control exclude: H8_INNER

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: H83
Name in latin: Dysfunctio labyrinthi

NAME	H8_LABYRDYSFUNC
CONTROL_EXCLUDE	H8_INNER
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H832
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H832
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Labyrinthine dysfunction based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	156	94	62
Only index persons	152	91	61
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	-	52.39	52.86
Only index persons	52.25	51.37	53.58

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	28	15	13
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	56.17	54.87	57.67

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

3.24

1.71

1.3

1.5

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

156

2.91

1.59

2.3

3.0

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

2.75

1.55

4.7

2.6

286.3

15.0

ng/l

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.79

1.41

1.4

1.9

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.90

1.39

1.3

1.4

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

132

2.36

1.33

7.7

11.1

4.1

e9/l

0.03

116

(3033658) Prothrombin time (PT) actual/Normal

2.23

1.13

6.3

4.4

74.0

89.3

—

(3042936) Bacteria identified in Isolate by Culture

2.11

0.87

1.5

2.1

—

(3022096) Basophils/100 leukocytes in Blood

1.95

0.86

7.9

5.9

0.9

0.7

0.63

(36304419) Bacteria [Presence] in Urine

2.04

0.86

2.8

3.1

—

(3000492) Spirometry study

0.00

0.84

0.0

1.4

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

1.93

0.71

1.8

1.7

0.8

1.2

mmol/l

—

(3002030) Lymphocytes/100 leukocytes in Blood

100

1.80

0.70

8.1

5.9

30.9

27.7

0.66

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

0.00

0.62

0.0

1.2

—

(42870588) Differential panel, method unspecified - Blood

1.70

0.53

7.6

5.2

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.65

0.51

2.6

3.2

—

(40758558) Short blood count panel - Blood

1.60

0.48

6.8

7.7

—

(3044640) Blood type and Crossmatch panel - Blood

1.60

0.46

2.2

2.4

—

(40768797) Stomach Pathology biopsy report

1.57

0.43

1.0

1.3

—

(3026989) Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma

0.00

0.42

0.0

4.0

—

4.3

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

0.00

0.42

0.0

1.2

—

159.2

—

(3030981) Hyaline casts [#/volume] in Urine by Automated count

0.00

0.42

0.0

1.8

—

0.0

—

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

0.00

0.41

0.0

2.3

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.00

0.41

0.0

1.2

—

(36660697) Celiac disease serology panel - Serum

0.00

0.41

0.0

1.2

—

(1761868) Lipid panel - Serum or Plasma

0.61

0.41

2.0

2.3

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.46

0.37

2.2

2.4

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

0.63

0.31

6.4

4.6

1.1

2.0

ug/l

—

(3009542) Hematocrit [Volume Fraction] of Blood

208

1.59

0.31

22.1

14.6

41.0

40.5

0.15

170

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

0.70

0.28

4.6

4.7

285.3

27.3

ng/l

—

(40768804) Tissue Pathology biopsy report

1.39

0.26

1.6

1.9

—

(40761511) CBC panel - Blood by Automated count

243

0.70

0.25

12.3

11.8

—

(4034850)

0.00

0.22

0.0

31.4

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.22

0.0

1.3

—

(3022621) pH of Urine by Test strip

0.00

0.22

0.0

2.4

—

(3025941) Bacteria identified in Stool by Culture

0.00

0.22

0.0

1.0

—

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

0.00

0.22

0.0

1.2

—

0.2

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.22

0.0

1.3

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

0.00

0.22

0.0

1.2

—

1.2

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.00

0.22

0.0

1.4

—

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

0.00

0.20

0.0

4.0

—

87.4

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

0.00

0.20

0.0

1.4

—

(3041096) Erythrocytes [Presence] in Urine by Automated

0.69

0.19

3.0

2.5

—

(3015377) Calcium [Moles/volume] in Serum or Plasma

0.73

0.18

1.7

3.7

2.4

2.3

mmol/l

—

(3044889) 12 lead EKG panel

167

0.78

0.17

4.3

3.8

—

(3037467) Urinalysis macro (dipstick) panel - Urine

153

1.28

0.17

3.4

3.8

—

(3003694) ABO and Rh group [Type] in Blood

1.09

0.09

1.2

1.4

—

(3026008) Bacteria identified in Urine by Culture

1.17

0.09

2.3

2.5

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

0.83

0.08

3.1

3.4

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

100

1.16

0.06

2.8

3.4

—

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

171

1.15

0.05

6.5

7.8

69.1

75.4

u/l

0.58

160

(3019473) Protein [Mass/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

476.6

—

(3020961) Endomysium IgA Ab [Titer] in Serum

0.00

0.0

1.0

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

1.1

—

(3022313) Gas panel - Capillary blood

0.00

0.0

3.8

—

(3032836) C peptide [Moles/volume] in Serum or Plasma --fasting

0.00

0.0

1.0

—

1.2

—

(3000330) Specific gravity of Urine by Test strip

0.00

0.0

3.4

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.0

1.6

—

(3038515) Glucose [Moles/volume] in Venous blood

0.00

0.0

3.4

—

5.7

—

(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.0

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

0.00

0.0

1.1

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.4

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

0.00

0.0

2.6

—

119.1

—

(3020044) Glucose [Moles/volume] in Cerebral spinal fluid

0.00

0.0

1.3

—

3.9

—

(3023420) DNA double strand Ab [Units/volume] in Serum

0.00

0.0

1.6

—

(1761482) Bacteria [#/volume] in Urine by Culture

0.00

0.0

3.8

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

0.00

0.0

1.2

—

(3001405) CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood

0.00

0.0

3.0

—

645.8

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

2.8

—

2.3

—

(3023368) Bacteria identified in Blood by Culture

1.04

0.00

4.3

4.5

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

10.0

—

54.4

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

1.0

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

0.00

0.0

4.1

—

26.2

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.4

—

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

0.00

0.0

1.2

—

(3015736) pH of Urine

1.03

0.00

2.1

3.7

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

0.00

0.0

1.4

—

(3009508) Creatinine [Moles/volume] in Urine

1.04

0.00

1.8

3.3

8.7

7.2

mmol/l

—

(3025271) CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood

0.00

0.0

2.8

—

0.1

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.3

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.02

0.00

2.8

4.6

—

(3045414) Leukocytes [Presence] in Urine

0.00

0.0

2.2

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.5

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.0

1.3

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.0

2.2

—

(3008037) Lactate [Moles/volume] in Venous blood

0.00

0.0

3.4

—

1.4

—

(3044290) Cell count panel - Cerebral spinal fluid

0.00

0.0

1.1

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

0.00

0.0

1.2

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.0

1.0

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.0

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.2

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.0

1.2

—

(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum

0.00

0.0

1.4

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

0.00

0.0

1.0

—

(3019150) Specific gravity of Urine by Refractometry

0.95

0.00

2.4

4.5

—

1.0

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

2.1

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

0.00

0.0

1.3

—

Mortality – FinRegistry

↥

Association

Association between endpoint H8_LABYRDYSFUNC and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H8_LABYRDYSFUNC.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: H8_LABYRDYSFUNC – Labyrinthine dysfunction

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Labyrinthine dysfunction

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints